207 related articles for article (PubMed ID: 14605329)
1. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
Montaner J; Fernández-Cadenas I; Molina CA; Monasterio J; Arenillas JF; Ribó M; Quintana M; Chacón P; Andreu AL; Alvarez-Sabín J
Stroke; 2003 Dec; 34(12):2851-5. PubMed ID: 14605329
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.
Montaner J; Molina CA; Monasterio J; Abilleira S; Arenillas JF; Ribó M; Quintana M; Alvarez-Sabín J
Circulation; 2003 Feb; 107(4):598-603. PubMed ID: 12566373
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.
Montaner J; Alvarez-Sabín J; Molina CA; Anglés A; Abilleira S; Arenillas J; Monasterio J
Stroke; 2001 Dec; 32(12):2762-7. PubMed ID: 11739970
[TBL] [Abstract][Full Text] [Related]
4. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
Castellanos M; Leira R; Serena J; Blanco M; Pedraza S; Castillo J; Dávalos A
Stroke; 2004 Jul; 35(7):1671-6. PubMed ID: 15166391
[TBL] [Abstract][Full Text] [Related]
5. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
[TBL] [Abstract][Full Text] [Related]
6. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
Castellanos M; Sobrino T; Millán M; García M; Arenillas J; Nombela F; Brea D; Perez de la Ossa N; Serena J; Vivancos J; Castillo J; Dávalos A
Stroke; 2007 Jun; 38(6):1855-9. PubMed ID: 17478737
[TBL] [Abstract][Full Text] [Related]
7. Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator.
Rodríguez-González R; Blanco M; Rodríguez-Yáñez M; Moldes O; Castillo J; Sobrino T
Atherosclerosis; 2013 Jan; 226(1):165-71. PubMed ID: 23218119
[TBL] [Abstract][Full Text] [Related]
8. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke.
Castellanos M; Leira R; Serena J; Pumar JM; Lizasoain I; Castillo J; Dávalos A
Stroke; 2003 Jan; 34(1):40-6. PubMed ID: 12511748
[TBL] [Abstract][Full Text] [Related]
9. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
[TBL] [Abstract][Full Text] [Related]
10. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Muhammad S; Planz O; Schwaninger M
Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
[TBL] [Abstract][Full Text] [Related]
11. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
Ribo M; Montaner J; Molina CA; Arenillas JF; Santamarina E; Quintana M; Alvarez-Sabín J
Stroke; 2004 Sep; 35(9):2123-7. PubMed ID: 15243150
[TBL] [Abstract][Full Text] [Related]
12. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke.
Saposnik G; Fang J; Kapral MK; Tu JV; Mamdani M; Austin P; Johnston SC; ;
Stroke; 2012 May; 43(5):1315-22. PubMed ID: 22308252
[TBL] [Abstract][Full Text] [Related]
13. Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients.
Fernández-Cadenas I; Del Río-Espínola A; Carrera C; Domingues-Montanari S; Mendióroz M; Delgado P; Rosell A; Ribó M; Giralt D; Quintana M; Castellanos M; Obach V; Martínez S; Freijo MM; Jiménez-Conde J; Roquer J; Martí-Fábregas J; Molina CA; Alvarez-Sabín J; Montaner J
Stroke; 2012 May; 43(5):1398-400. PubMed ID: 22496335
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study.
Kelly PJ; Morrow JD; Ning M; Koroshetz W; Lo EH; Terry E; Milne GL; Hubbard J; Lee H; Stevenson E; Lederer M; Furie KL
Stroke; 2008 Jan; 39(1):100-4. PubMed ID: 18063832
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
[TBL] [Abstract][Full Text] [Related]
16. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
[TBL] [Abstract][Full Text] [Related]
17. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
Millan M; Sobrino T; Castellanos M; Nombela F; Arenillas JF; Riva E; Cristobo I; García MM; Vivancos J; Serena J; Moro MA; Castillo J; Dávalos A
Stroke; 2007 Jan; 38(1):90-5. PubMed ID: 17138950
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer.
Rahimi Z; Yari K; Rahimi Z
Asian Pac J Cancer Prev; 2015; 16(3):1175-9. PubMed ID: 25735351
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
Cocho D; Borrell M; Martí-Fàbregas J; Montaner J; Castellanos M; Bravo Y; Molina-Porcel L; Belvís R; Díaz-Manera JA; Martínez-Domeño A; Martínez-Lage M; Millán M; Fontcuberta J; Martí-Vilalta JL
Stroke; 2006 Apr; 37(4):996-9. PubMed ID: 16497981
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry.
Dzialowski I; Pexman JH; Barber PA; Demchuk AM; Buchan AM; Hill MD;
Stroke; 2007 Jan; 38(1):75-9. PubMed ID: 17122437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
